arrow
T

Toshiyuki Harada

chiba university
H指数:34
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy of pembrolizumab plus pemetrexed in older patients with non-squamous NSCLC according to PD-L1 expression status: Results from the CJLSG1901 study

帕博利珠单抗联合培美曲塞在PD-L1表达状态不同的老年非鳞状NSCLC患者中的疗效:CJLSG1901研究的结果

2026-01-010
OAAI
Post COVID-19 condition in hospitalized survivors after one year of infection during the Alpha- and Delta-variant dominant waves in Japan: COVID-19 Recovery Study II
2025-01-011
OAAI
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301)
2024-11-012
OA
Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701)

非小细胞肺癌同步脑转移: 一项回顾性多中心研究 (热点1701) 的预后因素分析

2024-10-050
OAAI
Nintedanib plus Chemotherapy for Small Cell Lung Cancer with Comorbid Idiopathic Pulmonary Fibrosis

尼达尼布联合化疗治疗小细胞肺癌合并特发性肺纤维化

2024-04-014
PRE
High-precision rapid testing of omicron SARS-CoV-2 variants in clinical samples using AI-nanopore
2023-01-012
PRE
Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data

使用日本上市后所有病例监测数据对Pembrolizumab单药治疗NSCLC的真实数据分析

2022-11-013
OA
Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment
2022-11-011
OAAI
A Randomized Comparison of Nivolumab versus Nivolumab plus Docetaxel for Previously Treated Advanced or Recurrent ICI-Naive Non-Small Cell Lung Cancer: TORG1630
2022-08-1816
OAAI
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial
2022-03-3151
PRE